| 查看: 790 | 回复: 16 | |||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
英语翻译
|
|||
|
Dose response studies The Applicant has presented two phase 2 studies for the claimed indications (for cSSTI: Study 200 and for cIAI: Study 202). Study 200 was a randomized, open-label, comparison study of hospitalized subjects with complicated Skin and Soft Tissue infections in which 160 patients received either tigecycline 25 or 50 mg twice daily with an initial dose of 50 or 100 mg, respectively. The clinical data from this study indicated a trend toward a dose-related clinical cure response (67% and 74%, respectively) and dose-related pathogen eradication (56% and 70%). Also dose-safety relationships appeared evident for the adverse events (AEs) of nausea (22% and 35%) and vomiting (13% and 18%). Since tigecycline is intended for use in complicated infections, efficacy was favoured in benefit/risk -balance, and the greater dosage schedule (50 mg twice daily with an initial dose of 100 mg) was used in all consecutive clinical Phase II and III trials. Study 202 was a phase 2, multicenter, open-label study in hospitalized subjects with complicated intra-abdominal infections in which 111 subjects received an initial IV loading dose of 100 mg of tigecycline followed by 50 mg every 12 hours. Treatment continued for at least 5 days but not more than 14 days. There were no comparator or placebo groups. Overall, it appears that the choice of the dosage regimen for phase 3 studies is based on pharmacokinetic considerations as well as tolerability. The safety profile in these phase 2 studies is consistent with that seen in the larger database of phase 3 clinical trials. However, it should be highlighted that one case of Clostridium difficile associated colitis has been reported in Study 202. Apparently, this was the only one serious case reported of this adverse event for subjects in Phase 2 and 3 trials. Complicated intra-abdominal infections (cIAI) Methods Two pivotal phase 3 trials (studies 301 and 306) have been submitted in support of the indication complicated intra-abdominal infections. Study 301 was carried out in the Western hemisphere, and 306 in worldwide. The study protocols were similar in all essential points. Both phase 3 were multicenter, double-blind (third-party unblinded) studies in which 1568 hospitalised patients (approximately 800 patients per trial) with complicated intra-abdominal infections who were candidates for or had received a laparotomy, laparoscopy, or percutaneous drainage of an intraabdominal abscess were randomized. Key inclusion criteria were the followings: 1. Hospitalized male or female subjects, at least 18 years of age. 2. Candidate for, or had, a laparotomy, laparoscopy, or percutaneous drainage of an intra-abdominal abscess. 3. Complicated intra-abdominal infection, such as: a. An intra-abdominal abscess. b. An intra-abdominal abscess (including liver and spleen) that developed in a postoperative subject who received more than 48 hours but not more than 5 days of a nonstudy antibiotic and an intraabdominal culture was obtained from the infected site. c. Appendicitis complicated by perforation (grossly visible) and abscess or periappendicular abscess. d. Perforated diverticulitis complicated by abscess formation or faecal contamination. e. Complicated cholecystitis with evidence of perforation or empyema. f. Perforation of the large or small intestine with abscess or fecal contamination. g. Purulent peritonitis or peritonitis associated with faecal contamination. h. Gastric or duodenal ulcer perforation with symptoms lasting at least 24 hours before operation. i. Traumatic bowel perforation with symptoms lasting at least 12 hours before operation. 4. No more than 1 dose of an antibiotic (single broad-spectrum agent or 1 dose of each antibiotic in a combination regimen such as metronidazole, ampicillin,gentamicin) after the baseline intra-abdominal culture was obtained from the infected site. [ Last edited by 痴夷子皮 on 2011-1-10 at 13:07 ] |
回复此楼» 猜你喜欢
295分求调剂
已经有4人回复
-
294求调剂
已经有8人回复
-
山东双非院校考核超级无底线，领导幸灾乐祸，教师遭殃恐
已经有8人回复
-
0854求调剂
已经有25人回复
-
一志愿沪9，326求生物学调剂
已经有11人回复
-
322求调剂
已经有6人回复
-
本人女孩
已经有10人回复
-
二苯甲酮酸类衍生物
已经有4人回复
-
一志愿中科大材料与化工，353分还有调剂学校吗
已经有11人回复
-
335求调剂
已经有23人回复
» 抢金币啦！回帖就可以得到:
-
江西科技师范大学高分子化学与物理招生
+5/720
-
诚邀申报 | 潍坊学院“绿色催化新材料与光化学转化山东省工程研究中心“开放课题
+1/487
-
科研需求-硫化镍钴精矿样品
+1/399
-
青岛大学/康复大学导师课题组2026年博士研究生
+3/359
-
【坐标大连】92年本科男生，寻觅姻缘女生
+5/341
-
欧洲“CO2捕集与加氢催化转化”博士招聘（捷克-德国-斯洛文尼亚三国项目）
+1/90
-
当新能源不再是一个选择题
+1/88
-
复旦大学 课题组 2026年9月批入学-博士招聘
+1/85
-
硕士招生 吉林化工大学 功能多孔材料课题组招考研学生1-2名
+1/37
-
上海交通大学-电气工程学院-高温超导磁体-2026年入学全日制博士生招聘
+1/36
-
山东航空学院安全工程专业085702第三轮接收研究生调剂，欢迎咨询
+1/35
-
上海工作，94年的博士
+1/33
-
爱情短剧
+1/30
-
大连大学—六盘水师范学院联培硕士调剂
+1/9
-
C13、N15标记植物，助力土壤碳氮循环与地学研究实操
+1/8
-
省重点实验室招收调剂生，海洋生物专业，名额充足，可快速安排复试并出结果
+1/8
-
材料与化工专业还有大量指标，欢迎大家调剂，调剂系统已经开放
+1/7
-
【每日皆可乐】探秘细胞因子：趋化因子家族解析
+1/3
-
湖南理工大学 化学、化工调剂指标充足，录取率高
+1/2
-
安徽工程大学化学与环境工程学院2026级硕士研究生还有部分调剂名额-资源与环境专硕
+1/1
帖子如何关闭？ 17楼2011-01-16 18:39:31
5楼2011-01-10 13:31:48
6楼2011-01-10 13:37:57
7楼2011-01-10 13:40:17
